Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.145

-5.0%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: seminole	12/6/2013 9:41:23 AM
	of 3576

Mayo Clinic Article on Geron (GERN) Doesn't Offer a Lot New - Needham & Company9:34 AM ET, 12/06/2013 - Street Insider Geron Corporation (NASDAQ: GERN) is up 15% this morning after following an article yesterday by the Mayo Clinic describing the imetelstat data to be presented Monday at the American Society for Hematology (ASH) meeting. However, one analyst is not convinced that the articles has a lot of new info. Needham & Company analyst Chad Messer states, "In so far as this article reflects the actual presentation, we don't see a whole lot that is new beyond the unprecedented efficacy reported by the company in November. We remain positively inclined towards the data but feel investors should wait for full presentation, as well as Geron's investor event, on Monday to understand the full story. Even then we may not know important details about the company's plans for further development of imetelstat in myelofibrosis." For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here. Shares of Geron Corporation closed at $5.87 yesterday, with a 52 week range of $0.98-$7.79.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next